Objectives: The aim of this study was to assess the relationship between oral health-related quality of life, the nature of mucosal disease, and personality traits.
Methods: One hundred forty-nine patients seeking care for oral mucosal disease were recruited in this cross-sectional study conducted at the University Clinic of Dentistry in Vienna from June to December 2013. All participants agreed in answering two questionnaires: the Oral Health Impact Profile German version (OHIP-G), which assessed the perceived limitations of oral health-related quality of life and the Neuroticism Extraversion Openness Five-Factor Inventory (NEO-FFI), which evaluated five personality domains. A multiple linear regression was applied to examine the potential influence on OHIP scores.
Results: Bullous/erosive mucosal diseases and oral lichen planus patients (n = 73, 49% of total) reported the highest impact on oral health-related quality of life (OHIP total score 49.3 ± 35.7, p = 0.02). A highly significant influence of neuroticism, as a personality trait, was observed on oral health-related quality of life (p = 0.001). Women had significantly more restrictions (OHIP score 45.3 ± 32.2) compared to men (32.6 ± 30.1, p = 0.009).
Conclusions: Psychosocial factors such as personality traits, especially neuroticism, are significantly associated with quality of life ratings in patients with mucosal disease.
Clinical Relevance: Since mucosal diseases impact patient's daily living and quality of life while affected by their psychological profiles, this should be considered when formulating a therapeutic approach.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00784-014-1377-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lecanemab, a humanized IgG1 monoclonal antibody that binds with high affinity to amyloid-beta (Aβ) protofibrils, was formally evaluated as a treatment for early Alzheimer's disease in a phase 2 study (Study 201) and the phase 3 Clarity AD study. These trials both included an 18-month, randomized study (core) and an open-label extension (OLE) phase where eligible participants received open-label lecanemab for up to 30 months to date. Clinical (CDR-SB, ADAS-Cog14, and ADCS-MCI-ADL), biomarker (PET, Aβ42/40 ratio, and ptau181) and safety outcomes were evaluated.
View Article and Find Full Text PDFAlzheimer's disease pathophysiology is believed to involve various abnormalities, including those of amyloid beta (Ab) peptide and tau processing, inflammation, oxidative stress, and vascular risk factors. Aβ peptides exist in a dynamic continuum of conformational states from monomeric Aβ, to soluble progressively larger Aβ assemblies that include a range of low molecular weight oligomers to higher molecular weight protofibrils, and finally to insoluble fibrils (plaques). Various lines of evidence support the "amyloid hypothesis" that Aβ plays a central role in the pathogenesis of AD, and several immunotherapies have been developed to interact with this cascade in various different places which may reduce the number of soluble aggregates and insoluble Aβ fibrils deposited in the brain.
View Article and Find Full Text PDFBackground: Lecanemab is an approved anti-amyloid monoclonal antibody that binds with highest affinity to soluble Aβ protofibrils, which are more toxic than monomers or insoluble fibrils/plaque. In clinical studies, biweekly lecanemab treatment demonstrated a slowing of decline in clinical (global, cognitive, functional, and quality of life) outcomes, and reduction in brain amyloid in early Alzheimer's disease (AD). Herein, we describe the impact of lecanemab treatment on tau PET.
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
Stevenson University, Owings Mills, MD, USA.
Background: Most assisted living (AL) settings organize and provide opportunities for residents to participate in activities (e.g., exercise, music, arts and craft, cognitive activities, religious services, community outings).
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
University College London, London, United Kingdom.
Background: The progressive nature of dementia and the complex needs means that people living with dementia require tailored approaches to address their changing care needs over time. These include physical multimorbidity, psychological, behavioural, and cognitive symptoms and possible risks arising from these and helping family caregivers. However, provision of these interventions is highly variable between and within countries, partly due to uncertainty about their efficacy and scarce resources.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!